A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-07-04
Adverse events
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 54); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 58); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-28 (study day 72); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 124); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-11-25 (study day 130); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-18 (study day 153); relationship: not assessed
Data queries
No data queries.